Literature DB >> 33946881

1,3,4-Thiadiazoles Effectively Inhibit Proliferation of Toxoplasma gondii.

Lidia Węglińska1, Adrian Bekier2, Katarzyna Dzitko2, Barbara Pacholczyk-Sienicka3, Łukasz Albrecht3, Tomasz Plech4, Piotr Paneth5,6, Agata Paneth1.   

Abstract

Congenital and acquired toxoplasmosis caused by the food- and water-born parasite Toxoplasma gondii (T. gondii) is one of the most prevalent zoonotic infection of global importance. T. gondii is an obligate intracellular parasite with limited capacity for extracellular survival, thus a successful, efficient and robust host cell invasion process is crucial for its survival, proliferation and transmission. In this study, we screened a series of novel 1,3,4-thiadiazole-2-halophenylamines functionalized at the C5 position with the imidazole ring (1b-12b) for their effects on T. gondii host cell invasion and proliferation. To achieve this goal, these compounds were initially subjected to in vitro assays to assess their cytotoxicity on human fibroblasts and then antiparasitic efficacy. Results showed that all of them compare favorably to control drugs sulfadiazine and trimethoprim in terms of T. gondii growth inhibition (IC50) and selectivity toward the parasite, expressed as selectivity index (SI). Subsequently, the most potent of them with meta-fluoro 2b, meta-chloro 5b, meta-bromo 8b, meta-iodo 11b and para-iodo 12b substitution were tested for their efficacy in inhibition of tachyzoites invasion and subsequent proliferation by direct action on established intracellular infection. All the compounds significantly inhibited the parasite invasion and intracellular proliferation via direct action on both tachyzoites and parasitophorous vacuoles formation. The most effective was para-iodo derivative 12b that caused reduction in the percentage of infected host cells by 44% and number of tachyzoites per vacuole by 93% compared to non-treated host cells. Collectively, these studies indicate that 1,3,4-thiadiazoles 1b-12b, especially 12b with IC50 of 4.70 µg/mL and SI of 20.89, could be considered as early hit compounds for future design and synthesis of anti-Toxoplasma agents that effectively and selectively block the invasion and subsequent proliferation of T. gondii into host cells.

Entities:  

Keywords:  1,3,4-thiadiazole; SAR analysis; Toxoplasma gondii; cytotoxicity; genotoxicity

Year:  2021        PMID: 33946881     DOI: 10.3390/cells10051053

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  25 in total

1.  Is ocular toxoplasmosis caused by prenatal or postnatal infection?

Authors:  R E Gilbert; M R Stanford
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

Review 2.  Veterinary vaccines against Toxoplasma gondii.

Authors:  Elisabeth A Innes; Paul M Bartley; Stephen Maley; Frank Katzer; David Buxton
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

Review 3.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

Review 4.  Strain hypothesis of Toxoplasma gondii infection on the outcome of human diseases.

Authors:  J Xiao; R H Yolken
Journal:  Acta Physiol (Oxf)       Date:  2015-01-28       Impact factor: 6.311

Review 5.  Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.

Authors:  Yu Deng; Tao Wu; Shao-Qin Zhai; Cheng-Hong Li
Journal:  Eur J Med Chem       Date:  2019-09-19       Impact factor: 6.514

6.  Psychosis may be associated with toxoplasmosis.

Authors:  Sha Zhu
Journal:  Med Hypotheses       Date:  2009-05-20       Impact factor: 1.538

Review 7.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

Review 8.  Drug Resistance in Toxoplasma gondii.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Asal Tanzifi; Sargis A Aghayan; Ahmad Daryani
Journal:  Front Microbiol       Date:  2018-10-29       Impact factor: 5.640

9.  Case report of a neonate with ocular toxoplasmosis due to congenital infection: estimation of the percentage of ocular toxoplasmosis in Greece caused by congenital or acquired infection.

Authors:  Ioannis Asproudis; Ioannis Koumpoulis; Chris Kalogeropoulos; Georgios Sotiropoulos; Margarita Papassava; Miltiadis Aspiotis
Journal:  Clin Ophthalmol       Date:  2013-11-21

Review 10.  The global serological prevalence of Toxoplasma gondii in felids during the last five decades (1967-2017): a systematic review and meta-analysis.

Authors:  Mahbobeh Montazeri; Tahereh Mikaeili Galeh; Mahmood Moosazadeh; Shahabeddin Sarvi; Samira Dodangeh; Javad Javidnia; Mehdi Sharif; Ahmad Daryani
Journal:  Parasit Vectors       Date:  2020-02-17       Impact factor: 3.876

View more
  3 in total

Review 1.  Emerging Roles and Mechanisms of lncRNA FOXD3-AS1 in Human Diseases.

Authors:  Qinfan Yao; Xiuyuan Zhang; Dajin Chen
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

Review 2.  The Current Directions of Searching for Antiparasitic Drugs.

Authors:  Katarzyna Dziduch; Dominika Greniuk; Monika Wujec
Journal:  Molecules       Date:  2022-02-24       Impact factor: 4.411

3.  Exploring the Antiparasitic Activity of Tris-1,3,4-Thiadiazoles against Toxoplasma gondii-Infected Mice.

Authors:  Tahani M Almutairi; Nadjet Rezki; Mohamed Reda Aouad; Mohamed Hagar; Basant A Bakr; Moaaz T Hamed; Maha Khairy Hassen; Bassma H Elwakil; Esraa Abdelhamid Moneer
Journal:  Molecules       Date:  2022-03-30       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.